{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T23:00:23Z","timestamp":1772751623039,"version":"3.50.1"},"reference-count":47,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2010,3,22]],"date-time":"2010-03-22T00:00:00Z","timestamp":1269216000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"Krembil Neuroscience Fund"},{"name":"Edmond Safra Foundation"},{"name":"Cure Parkinson's Trust"},{"name":"Prinses Beatrix Fonds"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Movement Disorders"],"published-print":{"date-parts":[[2010,7,30]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Levodopa\u2010induced motor complications, including dyskinesia and wearing off, are troublesome side effects of treatment and impair quality of life in Parkinson's disease (PD) patients. The use of nondopaminergic agents as adjuncts to levodopa are potential options for managing these problems. Here, we asses the ability of the clinically available, selective histamine H<jats:sub>2<\/jats:sub> antagonist, famotidine (1, 3, and 30 mg\/kg) to treat levodopa\u2010induced dyskinesia and wearing off in the 1\u2010methyl\u20104\u2010phenyl\u20101,2,3,6\u2010tetrahydropyridine (MPTP)\u2010macaque model of PD. Famotidine (3 mg\/kg) increased peak activity, enhanced peak anti\u2010parkinsonian action (1 and 3 mg\/kg), and extended duration of action (3 mg\/kg, by 38%) of a low dose of levodopa (compared to low dose levodopa alone). Enhancement of anti\u2010parkinsonian actions of low dose levodopa by famotidine (3 mg\/kg) was associated with only mild, nondisabling dystonia. Famotidine had no effect on the anti\u2010parkinsonian actions of high dose levodopa (compared to high dose levodopa alone). However, famotidine (1, 3, and 30 mg\/kg) had a significant effect on chorea, but not dystonia, induced by high dose levodopa (compared to high dose levodopa alone). Famotidine increased high dose levodopa\u2013induced \u201cgood quality\u201d on time, i.e., on time not associated with disabling dyskinesia, by up to 28% (compared to high dose levodopa alone). In conclusion, famotidine, a drug currently available for use in the clinic, can enhance the peak\u2010dose anti\u2010parkinsonian actions and extend total duration of action of a low dose of levodopa, without producing disabling dyskinesia. Furthermore, in combination with a higher dose of levodopa, famotidine can reduce peak\u2010dose levodopa\u2010induced chorea and improve the quality of on\u2010time. \u00a9 2010 Movement Disorder Society<\/jats:p>","DOI":"10.1002\/mds.23069","type":"journal-article","created":{"date-parts":[[2010,3,22]],"date-time":"2010-03-22T16:30:54Z","timestamp":1269275454000},"page":"1379-1390","source":"Crossref","is-referenced-by-count":42,"title":["Effect of histamine H<sub>2<\/sub> receptor antagonism on levodopa\u2013induced dyskinesia in the MPTP\u2010macaque model of Parkinson's disease"],"prefix":"10.1002","volume":"25","author":[{"given":"Tom H.","family":"Johnston","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"van der Meij","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan M.","family":"Brotchie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan H.","family":"Fox","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2010,7,23]]},"reference":[{"key":"e_1_2_8_2_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.21743"},{"key":"e_1_2_8_3_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.20324"},{"key":"e_1_2_8_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.20464"},{"key":"e_1_2_8_5_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000215250.82576.87"},{"key":"e_1_2_8_6_2","doi-asserted-by":"publisher","DOI":"10.1006\/exnr.2000.7362"},{"key":"e_1_2_8_7_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1471-4159.2002.00871.x"},{"key":"e_1_2_8_8_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0706440"},{"key":"e_1_2_8_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0306-4522(97)00010-9"},{"key":"e_1_2_8_10_2","doi-asserted-by":"publisher","DOI":"10.1006\/nbdi.2001.0413"},{"key":"e_1_2_8_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/syn.890150306"},{"key":"e_1_2_8_12_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002109900097"},{"key":"e_1_2_8_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.20828"},{"issue":"1","key":"e_1_2_8_14_2","first-page":"9A","article-title":"Pharmacology of H2\u2010receptor antagonists: an overview","volume":"17","author":"Schunack W","year":"1989","journal-title":"J Int Med Res"},{"key":"e_1_2_8_15_2","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.108.144097"},{"key":"e_1_2_8_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2008.11.010"},{"key":"e_1_2_8_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2003.11.065"},{"key":"e_1_2_8_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2008.11.001"},{"key":"e_1_2_8_19_2","series-title":"Recent developments in Parkinson's disease","first-page":"153","author":"Fahn S","year":"1987"},{"key":"e_1_2_8_20_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.22340"},{"key":"e_1_2_8_21_2","doi-asserted-by":"publisher","DOI":"10.1159\/000131893"},{"key":"e_1_2_8_22_2","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.105.094052"},{"key":"e_1_2_8_23_2","first-page":"1","volume-title":"Pepcid (famotidine) tablet product monograph","author":"Merck\u2010Frosst","year":"2007"},{"key":"e_1_2_8_24_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199120030-00004"},{"key":"e_1_2_8_25_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002826-199619040-00007"},{"key":"e_1_2_8_26_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02259665"},{"key":"e_1_2_8_27_2","article-title":"Patient perception of dyskinesia in Parkinson's disease","author":"Hung SW","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"e_1_2_8_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)71083-7"},{"key":"e_1_2_8_29_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.870130507"},{"key":"e_1_2_8_30_2","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.104.066191"},{"key":"e_1_2_8_31_2","doi-asserted-by":"publisher","DOI":"10.1002\/1531-8257(200009)15:5<873::AID-MDS1017>3.0.CO;2-I"},{"key":"e_1_2_8_32_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002826-200003000-00004"},{"key":"e_1_2_8_33_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1460-9568.2000.00267.x"},{"key":"e_1_2_8_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/0304-3940(94)90279-8"},{"key":"e_1_2_8_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neures.2005.07.008"},{"key":"e_1_2_8_36_2","doi-asserted-by":"publisher","DOI":"10.1152\/jn.00148.2006"},{"key":"e_1_2_8_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0166-4328(01)00223-6"},{"key":"e_1_2_8_38_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002109900098"},{"key":"e_1_2_8_39_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.870020107"},{"key":"e_1_2_8_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tins.2007.07.008"},{"key":"e_1_2_8_41_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00702-004-0251-7"},{"key":"e_1_2_8_42_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002826-199410000-00015"},{"key":"e_1_2_8_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-6757(99)90120-1"},{"key":"e_1_2_8_44_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0736-4679(01)00325-0"},{"key":"e_1_2_8_45_2","first-page":"53","article-title":"Dopamine transmission in DYT1 dystonia","volume":"94","author":"Augood SJ","year":"2004","journal-title":"Adv Neurol"},{"key":"e_1_2_8_46_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.10549"},{"key":"e_1_2_8_47_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(06)70574-9"},{"key":"e_1_2_8_48_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1472-8206.1994.tb00789.x"}],"container-title":["Movement Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fmds.23069","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fmds.23069","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mds.23069","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T09:59:42Z","timestamp":1760954382000},"score":1,"resource":{"primary":{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/10.1002\/mds.23069"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,7,23]]},"references-count":47,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2010,7,30]]}},"alternative-id":["10.1002\/mds.23069"],"URL":"https:\/\/doi.org\/10.1002\/mds.23069","archive":["Portico"],"relation":{},"ISSN":["0885-3185","1531-8257"],"issn-type":[{"value":"0885-3185","type":"print"},{"value":"1531-8257","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,7,23]]}}}